Aleksandar F. Radovic-Moreno1, Benjamin A. Teply2, Jason Fuller2, Frank Gu2, Etgar Levy-Nissenbaum2, Robert Langer3, and Omid C. Farokhzad4. (1) Harvard-MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology, 45 Carleton St, E25-342, Cambridge, MA 02142, (2) Department of Chemical Engineering, Massachusetts Institute of Technology, 45 Carleton St, E25-342, Cambridge, MA 02142, (3) Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Room E25-342, Cambridge, MA 02139, (4) Department of Anesthesiology, Harvard Medical School, 75 Francis St, Boston, MA 02155
There is a need for the development of cell-, or tissue-specific delivery vehicles for cancer therapeutic and diagostic applications. Targeted nanoparticle formulations have been identified as one possible method for achieving the required specificity, leading to an exponential rise in the number of reports in the literature based on these technologies. We hypothesized that a systematic approach for optimizing the biochemical and physical properties of these vehicles may speed their translation to the clinic. Herein, we report the development and evaluation of an array of poly(D,L-lactide)-b-poly(ethylene glycol) nanoparticles as a tool for targeted delivery optimization.